Focused On-demand Libraries - Receptor.AI Collaboration


Explore the Potential with AI-Driven Innovation

This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.


From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Reaxense aids in their synthesis and provision.


The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.


We utilise our cutting-edge, exclusive workflow to develop focused libraries for enzymes.


 

Fig. 1. The screening workflow of Receptor.AI

The method includes detailed molecular simulations of the catalytic and allosteric binding pockets, along with ensemble virtual screening that considers their conformational flexibility. In the design of modulators, structural changes induced by reaction intermediates are taken into account to enhance activity and selectivity.


Key features that set our library apart include:


  • The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.

  • The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.

  • With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.

  • Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.


PARTNER
Receptor.AI
 
UPACC
O15269

UPID:
SPTC1_HUMAN

ALTERNATIVE NAMES:
Long chain base biosynthesis protein 1; Serine-palmitoyl-CoA transferase 1

ALTERNATIVE UPACC:
O15269; A8K681; Q5VWB4; Q96IX6

BACKGROUND:
The enzyme Serine palmitoyltransferase 1, also known as Long chain base biosynthesis protein 1, is crucial for sphingolipid synthesis, impacting cell structure and signaling. Its activity with SPTLC2 or SPTLC3 influences the preference for specific CoA substrates, affecting lipid composition and cellular health. SPTLC1's function is vital for maintaining adipocyte health and systemic metabolic homeostasis.

THERAPEUTIC SIGNIFICANCE:
Given its involvement in hereditary sensory and autonomic neuropathy 1A, a disorder marked by sensory abnormalities and motor issues, targeting Serine palmitoyltransferase 1 could offer innovative approaches to mitigate these debilitating symptoms and improve quality of life for affected individuals.

Looking for more information on this library or underlying technology? Fill out the form below and we will be in touch with all the details you need.